Prequine® Ostenil 20mg


Prequine® Ostenil 20mg


About the product


Each ml contains: Sodium hyaluronate from fermentation and sodium chloride 10 mg
Disodium phosphate, Sodium dihydrogenphosphate
Water for injections

Medical device.
Synovial fluid, which is viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints, particularly the large weight bearing joints, where it ensures normal, painless movement due to its lubricating and shock-absorbing properties. It is also responsible for the nutrition of the cartilage.

Pain and restricted mobility in degenerative and traumatic changes of the knee joint and other synovial joints. In degenerative joint disorders such as osteoarthritis, the viscoelasticity of the synovial fluid is markedly reduced thereby decreasing its lubricating and shockabsorbing functions. This increases mechanical loading of the joint and cartilage destruction which ultimately results in pain and restricted mobility of the affected joint. Supplementing this synovial fluid with intra-articular injections of highly purified hyaluronic acid can ameliorate the viscoelastic properties synovial fluid. This improves its lubricating and shock-absorbing functions and reduces mechanical overload of the joint. As a rule this results in a decrease in pain and an improvement in joint mobility which may last for several months after a treatment cycle.

Dosage and administration:
Inject Ostenil into the affected joint once a week for a total of 3 - 5 injections. Several joint may be treated at the same time. Repeat treatment cycles may be administered as required. In case of joint effusion it is advisable to reduce the effusion by aspiration, rest, application of an ice pack and/or intra articular corticosteroid injection. Treatment with Ostenil can be started two to three days later.

Adverse Reactions:
Local secondary phenomena such as pain, sensation of heat, redness and swelling may occur in the joint treated with Ostenil. Application of an ice pack for 5 – 10 minutes onto the treated joint will reduce the incidence of these events.

Caution should be exercised in patients with known hypersensitivity to drugs. The general precautions for intra-articular injections should be observed, including measures to avoid joint infections. Ostenil should be injected accurately into the joint cavity, if necessary under imaging control. Avoid injections into blood vessels or surrounding tissues! As no clinical evidence is available on the use of hyaluronic acid in children, pregnant and lactating women or in inflammatory joint disease such as rheumatoid arthritis or Bechterew disease, treatment with Ostenil is not recommended in these cases. Do not use if pre-filled syringe or sterile pack are damaged. Any solution not used immediately after opening must be discarded.

Ostenil should not be used in patients with ascertained hypersensitivity to one of the constituents.

Store at 2 – 25°C.
Keep out of reach and sight of children.

One pre-filled syringe of 20mg / 2 ml

KD 12.50